呼吸训练器

Respiratory Muscle Trainer

Efficacy:

  • To enhance lung ventilation
  • To strengthen postoperative complications
  • To prevent pulmonary atelectasis
  • To improve the ability of independent coughing
  • To help clear sputum

Mobile No.: +86 157 2148 5268

Application Scenarios

Respiratory muscle strength training and autonomic sputum excretion for patients with
respiratory diseases and users who need to improve their exercise tolerance

Product advantages

Other Products

Company Overview

Shanghai SonmolTech Co., Ltd., established in 2014, is a technology-based company dedicated to changing the status of prevention and treatment of chronic diseases in China.
Pitching in respiratory diseases (COPD & asthma), on the one hand, the company builds a hospital-oriented auxiliary analysis model of common respiratory diseases with the lung function big data as the core to help hospitals and doctors improve the diagnosis and treatment capacities of respiratory diseases. On the other hand, it collects out-of-hospital pathological information through intelligent hardware, oriented to patients with chronic respiratory diseases. By resorting to mobile and WeChat Apps, the company connects the data in and out of the hospital, providing a convenient platform for out-of-hospital remote follow-up and disease management of for patients with chronic diseases.
The company is provided with strong R&D capabilities in the diagnosis and management of respiratory diseases, and has many intellectual property rights such as patents for invention, trademarks and software copyrights, as well as a R&D base more than 300m2 equipped with complete R&D equipment and instruments. The R&D team is composed of multi-disciplinary professional R&D technicians, accounting for 70% of the company's total staff, covering many professional fields such as medicine, machine learning algorithms, software, and embedding technology. SonmolTech has ranked among the best entrepreneurial firms related to the diagnosis and treatment of respiratory diseases in China. Up to now, the company has launched a number of clinical research cooperation projects with a number of grade 3 and first-class hospitals and governmental health departments, receiving a wide recognition of the industry.